Covered recipient · General Payments record
DANIELE MARIN
Allopathic & Osteopathic Physicians Radiology Diagnostic Radiology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2024 · Entire year
$56,650.36
51 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2024 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $37,750.00 | 36 |
| Travel and Lodging | $18,464.78 | 7 |
| Food and Beverage | $435.58 | 8 |
By paying entity
PY2024 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| PFIZER INC. | $36,175.00 | 31 |
| Siemens Medical Solutions USA, Inc. | $18,900.36 | 15 |
| Incyte Corporation | $1,575.00 | 5 |
Page 2 of 2; records 51–51 of 51 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
DANIELE MARIN
NPI 1407152283 · CMS profile ID 716637
Allopathic & Osteopathic Physicians / Radiology / Diagnostic Radiology
DURHAM, NC
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 2; records 51–51 of 51 matching records. This page contains 1 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1407152283?year=2024&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- DANIELE MARIN, NPI 1407152283, CMS profile ID 716637. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–51 of 51 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1407152283?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- APA 7
- IndustryPayments. (2026). DANIELE MARIN, NPI 1407152283, CMS profile ID 716637. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–51 of 51 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1407152283?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- Bluebook
- DANIELE MARIN, NPI 1407152283, CMS profile ID 716637, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–51 of 51 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1407152283?year=2024&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2024
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30
51 matching records · $56,650.36 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–51 of 51.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| PFIZER INC. | $2,690.00 | 01/11/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131200966 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $104,084.76 | 39 |
| PY2025 | Principal investigator | $430,375.00 | 19 |
| PY2024 | Recipient | $21,378.98 | 15 |
| PY2024 | Principal investigator | $570,249.94 | 42 |
| PY2023 | Recipient | $9,720.00 | 15 |
| PY2023 | Principal investigator | $1,147,318.00 | 22 |
| PY2022 | Recipient | $38,910.00 | 22 |
| PY2022 | Principal investigator | $141,147.50 | 40 |
| PY2021 | Recipient | $106,016.68 | 22 |
| PY2021 | Principal investigator | $159,253.14 | 31 |
| PY2020 | Recipient | $73,989.83 | 24 |
| PY2020 | Principal investigator | $140,881.64 | 12 |
| PY2019 | Recipient | $33,274.00 | 10 |
| PY2019 | Principal investigator | $95,225.28 | 7 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
58 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Boehringer Ingelheim Espana S.A. | $35,160.00 | 12/19/2025 | Non-covered Recipient Entity GI Reviewers, LLC | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220577698 |
| Recipient | Ipsen Innovation | $416.00 | 12/04/2025 | Covered Recipient Physician | A Phase II, Randomized, Open-label Study to Assess the Efficacy, Safety, and Pharmacokinetics (PK) of Maintenance Cabozantinib (XL184) Plus Best Supportive Care (BSC) Versus BSC in Children, Adolescents and Young Adults (AYA) With Unresectable Residual Osteosarcoma Either at Diagnosis or at First Relapse After Standard Treatment | No dispute reported | 06/30/2026 | 1184302787 |
| Principal investigator 1 | Boehringer Ingelheim Espana S.A. | $9,500.00 | 11/14/2025 | Non-covered Recipient Entity GI Reviewers, LLC | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220577696 |
| Recipient | Ipsen Innovation | $208.00 | 11/06/2025 | Covered Recipient Physician | A Phase II, Randomized, Open-label Study to Assess the Efficacy, Safety, and Pharmacokinetics (PK) of Maintenance Cabozantinib (XL184) Plus Best Supportive Care (BSC) Versus BSC in Children, Adolescents and Young Adults (AYA) With Unresectable Residual Osteosarcoma Either at Diagnosis or at First Relapse After Standard Treatment | No dispute reported | 06/30/2026 | 1184302785 |
| Recipient | GlaxoSmithKline, LLC. | $5,724.09 | 10/15/2025 | Covered Recipient Physician | A PHASE 2, SINGLE-ARM, OPEN-LABEL STUDY WITH DOSTARLIMAB MONOTHERAPY I | No dispute reported | 06/30/2026 | 1192107424 |
| Recipient | GlaxoSmithKline, LLC. | $4,252.13 | 10/15/2025 | Covered Recipient Physician | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M | No dispute reported | 06/30/2026 | 1192107485 |
| Principal investigator 1 | Boehringer Ingelheim Espana S.A. | $2,440.00 | 10/09/2025 | Non-covered Recipient Entity GI Reviewers, LLC | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220577692 |
| Principal investigator 1 | Boehringer Ingelheim Espana S.A. | $1,455.00 | 10/03/2025 | Non-covered Recipient Entity GI Reviewers, LLC | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220577694 |
| Recipient | GlaxoSmithKline, LLC. | $2,684.68 | 09/16/2025 | Covered Recipient Physician | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M | No dispute reported | 06/30/2026 | 1192109893 |
| Recipient | GlaxoSmithKline, LLC. | $2,684.68 | 09/16/2025 | Covered Recipient Physician | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M | No dispute reported | 06/30/2026 | 1192109898 |
| Recipient | GlaxoSmithKline, LLC. | $2,550.91 | 09/16/2025 | Covered Recipient Physician | A PHASE 2, SINGLE-ARM, OPEN-LABEL STUDY WITH DOSTARLIMAB MONOTHERAPY I | No dispute reported | 06/30/2026 | 1192109911 |
| Principal investigator 1 | Gilead Sciences, Inc. | $5,340.00 | 08/26/2025 | Non-covered Recipient Entity RADMD LLC | Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer After Failure of Platinum-Based Regimen or Anti-PD-1/PD-L1 Based Immunotherapy | No dispute reported | 06/30/2026 | 1229212319 |
| Recipient | GlaxoSmithKline, LLC. | $1,712.73 | 08/10/2025 | Covered Recipient Physician | A PHASE 2, SINGLE-ARM, OPEN-LABEL STUDY WITH DOSTARLIMAB MONOTHERAPY I | No dispute reported | 06/30/2026 | 1192107435 |
| Recipient | GlaxoSmithKline, LLC. | $2,401.20 | 08/10/2025 | Covered Recipient Physician | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M | No dispute reported | 06/30/2026 | 1192109887 |
| Recipient | GlaxoSmithKline, LLC. | $2,501.25 | 07/15/2025 | Covered Recipient Physician | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M | No dispute reported | 06/30/2026 | 1192107402 |
| Recipient | GlaxoSmithKline, LLC. | $1,371.36 | 07/15/2025 | Covered Recipient Physician | A PHASE 2, SINGLE-ARM, OPEN-LABEL STUDY WITH DOSTARLIMAB MONOTHERAPY I | No dispute reported | 06/30/2026 | 1192107464 |
| Principal investigator 1 | Gilead Sciences, Inc. | $10,020.00 | 07/10/2025 | Non-covered Recipient Entity RADMD LLC | Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer After Failure of Platinum-Based Regimen or Anti-PD-1/PD-L1 Based Immunotherapy | No dispute reported | 06/30/2026 | 1229212327 |
| Principal investigator 1 | Boehringer Ingelheim Espana S.A. | $36,895.00 | 07/08/2025 | Non-covered Recipient Entity GI Reviewers, LLC | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220577690 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $60.00 | 07/02/2025 | Covered Recipient Physician | A TWO-PART RANDOMIZED, PHASE 3 STUDY OF COMBINATIONS OF CEMIPLIMAB (ANTI-PD-1 ANTIBODY) AND PLATINUM-BASED DOUBLET CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1184120047 |
| Principal investigator 1 | Amgen Inc. | $1,225.00 | 06/19/2025 | Non-covered Recipient Entity GI REVIEWERS LLC | A Randomized, Double-Blind Study to Compare Efficacy, Pharmacokinetics, Safety, and Immunogenicity Between ABP 234 and Keytruda (Pembrolizumab) in Subjects With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1246641846 |
| Principal investigator 1 | Boehringer Ingelheim Espana S.A. | $22,625.00 | 06/19/2025 | Non-covered Recipient Entity GI Reviewers, LLC | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220577688 |
| Principal investigator 1 | Gilead Sciences, Inc. | $28,860.00 | 06/19/2025 | Non-covered Recipient Entity RADMD LLC | Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer After Failure of Platinum-Based Regimen or Anti-PD-1/PD-L1 Based Immunotherapy | No dispute reported | 06/30/2026 | 1229212336 |
| Recipient | GlaxoSmithKline, LLC. | $3,890.00 | 06/19/2025 | Covered Recipient Physician | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER S | No dispute reported | 06/30/2026 | 1192107383 |
| Recipient | GlaxoSmithKline, LLC. | $2,238.48 | 06/11/2025 | Covered Recipient Physician | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M | No dispute reported | 06/30/2026 | 1192107068 |
| Recipient | GlaxoSmithKline, LLC. | $1,114.54 | 06/11/2025 | Covered Recipient Physician | A PHASE 2, SINGLE-ARM, OPEN-LABEL STUDY WITH DOSTARLIMAB MONOTHERAPY I | No dispute reported | 06/30/2026 | 1192107410 |
| Recipient | GlaxoSmithKline, LLC. | $562.50 | 06/11/2025 | Covered Recipient Physician | A PHASE 2, RANDOMIZED, OPEN-LABEL, PLATFORM STUDY UTILIZING A MASTER P | No dispute reported | 06/30/2026 | 1192107480 |
| Principal investigator 1 | Gilead Sciences, Inc. | $13,440.00 | 06/05/2025 | Non-covered Recipient Entity RADMD LLC | Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer After Failure of Platinum-Based Regimen or Anti-PD-1/PD-L1 Based Immunotherapy | No dispute reported | 06/30/2026 | 1229212347 |
| Principal investigator 1 | Boehringer Ingelheim Espana S.A. | $6,215.00 | 05/15/2025 | Non-covered Recipient Entity GI Reviewers, LLC | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220577686 |
| Recipient | GlaxoSmithKline, LLC. | $1,667.50 | 05/13/2025 | Covered Recipient Physician | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M | No dispute reported | 06/30/2026 | 1192107074 |
| Recipient | GlaxoSmithKline, LLC. | $3,262.50 | 05/13/2025 | Covered Recipient Physician | A PHASE 2, RANDOMIZED, OPEN-LABEL, PLATFORM STUDY UTILIZING A MASTER P | No dispute reported | 06/30/2026 | 1192107364 |
| Recipient | GlaxoSmithKline, LLC. | $2,092.27 | 05/13/2025 | Covered Recipient Physician | A PHASE 2, SINGLE-ARM, OPEN-LABEL STUDY WITH DOSTARLIMAB MONOTHERAPY I | No dispute reported | 06/30/2026 | 1192107417 |
| Principal investigator 1 | Amgen Inc. | $26,342.50 | 05/12/2025 | Non-covered Recipient Entity GI REVIEWERS LLC | A Randomized, Double-Blind Study Evaluating the Efficacy, Safety, and Immunogenicity of ABP 206 Compared With OPDIVO (Nivolumab) in Subjects With Treatment-Nave Unresectable or Metastatic Melanoma | No dispute reported | 06/30/2026 | 1246641825 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $900.00 | 05/08/2025 | Covered Recipient Physician | A TWO-PART RANDOMIZED, PHASE 3 STUDY OF COMBINATIONS OF CEMIPLIMAB (ANTI-PD-1 ANTIBODY) AND PLATINUM-BASED DOUBLET CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1184120045 |
| Recipient | GlaxoSmithKline, LLC. | $2,405.29 | 04/15/2025 | Covered Recipient Physician | A PHASE 2, SINGLE-ARM, OPEN-LABEL STUDY WITH DOSTARLIMAB MONOTHERAPY I | No dispute reported | 06/30/2026 | 1192107396 |
| Recipient | GlaxoSmithKline, LLC. | $2,934.80 | 04/15/2025 | Covered Recipient Physician | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M | No dispute reported | 06/30/2026 | 1192107468 |
| Recipient | GlaxoSmithKline, LLC. | $7,441.00 | 04/15/2025 | Covered Recipient Physician | A PHASE 2, RANDOMIZED, OPEN-LABEL, PLATFORM STUDY UTILIZING A MASTER P | No dispute reported | 06/30/2026 | 1192109920 |
| Principal investigator 1 | Boehringer Ingelheim Espana S.A. | $3,780.00 | 04/10/2025 | Non-covered Recipient Entity GI Reviewers, LLC | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220577684 |
| Principal investigator 1 | Gilead Sciences, Inc. | $1,000.00 | 04/10/2025 | Non-covered Recipient Entity RADMD LLC | Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer After Failure of Platinum-Based Regimen or Anti-PD-1/PD-L1 Based Immunotherapy | No dispute reported | 06/30/2026 | 1229212361 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $175.00 | 04/10/2025 | Covered Recipient Physician | A GLOBAL, RANDOMISED, PHASE 3, OPEN-LABEL STUDY OF REGN2810 (ANTI-PD 1 ANTIBODY) VERSUS PLATINUM BASED CHEMOTHERAPY IN FIRST LINE TREATMENT OF PATIENTS WITH ADVANCED OR METASTATIC PD L1+NON-SMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1184120041 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $700.00 | 04/10/2025 | Covered Recipient Physician | A GLOBAL, RANDOMISED, PHASE 3, OPEN-LABEL STUDY OF REGN2810 (ANTI-PD 1 ANTIBODY) VERSUS PLATINUM BASED CHEMOTHERAPY IN FIRST LINE TREATMENT OF PATIENTS WITH ADVANCED OR METASTATIC PD L1+NON-SMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1184120043 |
| Principal investigator 1 | Boehringer Ingelheim Espana S.A. | $43,480.00 | 04/03/2025 | Non-covered Recipient Entity GI Reviewers, LLC | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220577680 |
| Principal investigator 1 | Boehringer Ingelheim Espana S.A. | $2,325.00 | 04/03/2025 | Non-covered Recipient Entity GI Reviewers, LLC | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220577682 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $960.00 | 04/01/2025 | Covered Recipient Physician | A TWO-PART RANDOMIZED, PHASE 3 STUDY OF COMBINATIONS OF CEMIPLIMAB (ANTI-PD-1 ANTIBODY) AND PLATINUM-BASED DOUBLET CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1184120037 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $1,320.00 | 04/01/2025 | Covered Recipient Physician | A TWO-PART RANDOMIZED, PHASE 3 STUDY OF COMBINATIONS OF CEMIPLIMAB (ANTI-PD-1 ANTIBODY) AND PLATINUM-BASED DOUBLET CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1184120039 |
| Recipient | GlaxoSmithKline, LLC. | $1,344.55 | 03/15/2025 | Covered Recipient Physician | A PHASE 2, SINGLE-ARM, OPEN-LABEL STUDY WITH DOSTARLIMAB MONOTHERAPY I | No dispute reported | 06/30/2026 | 1192107390 |
| Recipient | GlaxoSmithKline, LLC. | $15,149.50 | 03/13/2025 | Covered Recipient Physician | A PHASE 2, RANDOMIZED, OPEN-LABEL, PLATFORM STUDY UTILIZING A MASTER P | No dispute reported | 06/30/2026 | 1192107378 |
| Recipient | GlaxoSmithKline, LLC. | $761.25 | 03/13/2025 | Covered Recipient Physician | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M | No dispute reported | 06/30/2026 | 1192107474 |
| Recipient | GlaxoSmithKline, LLC. | $362.50 | 02/12/2025 | Covered Recipient Physician | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M | No dispute reported | 06/30/2026 | 1192107372 |
| Recipient | GlaxoSmithKline, LLC. | $8,552.63 | 02/12/2025 | Covered Recipient Physician | A PHASE 2, RANDOMIZED, OPEN-LABEL, PLATFORM STUDY UTILIZING A MASTER P | No dispute reported | 06/30/2026 | 1192109905 |
| Recipient | GlaxoSmithKline, LLC. | $1,530.00 | 02/11/2025 | Covered Recipient Physician | A PHASE 2, SINGLE-ARM, OPEN-LABEL STUDY WITH DOSTARLIMAB MONOTHERAPY I | No dispute reported | 06/30/2026 | 1192107062 |
| Recipient | Ipsen Innovation | $75.00 | 02/06/2025 | Covered Recipient Physician | A Phase II, Randomized, Open-label Study to Assess the Efficacy, Safety, and Pharmacokinetics (PK) of Maintenance Cabozantinib (XL184) Plus Best Supportive Care (BSC) Versus BSC in Children, Adolescents and Young Adults (AYA) With Unresectable Residual Osteosarcoma Either at Diagnosis or at First Relapse After Standard Treatment | No dispute reported | 06/30/2026 | 1184302783 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $420.00 | 02/06/2025 | Covered Recipient Physician | A TWO-PART RANDOMIZED, PHASE 3 STUDY OF COMBINATIONS OF CEMIPLIMAB (ANTI-PD-1 ANTIBODY) AND PLATINUM-BASED DOUBLET CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1184120035 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $720.00 | 01/21/2025 | Covered Recipient Physician | A TWO-PART RANDOMIZED, PHASE 3 STUDY OF COMBINATIONS OF CEMIPLIMAB (ANTI-PD-1 ANTIBODY) AND PLATINUM-BASED DOUBLET CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER | No dispute reported | 06/30/2026 | 1184120033 |
| Recipient | GlaxoSmithKline, LLC. | $1,083.87 | 01/15/2025 | Covered Recipient Physician | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M | No dispute reported | 06/30/2026 | 1192107429 |
| Recipient | GlaxoSmithKline, LLC. | $14,850.00 | 01/15/2025 | Covered Recipient Physician | A PHASE 2, RANDOMIZED, OPEN-LABEL, PLATFORM STUDY UTILIZING A MASTER P | No dispute reported | 06/30/2026 | 1192107441 |
| Recipient | GlaxoSmithKline, LLC. | $1,004.55 | 01/15/2025 | Covered Recipient Physician | A PHASE 2, SINGLE-ARM, OPEN-LABEL STUDY WITH DOSTARLIMAB MONOTHERAPY I | No dispute reported | 06/30/2026 | 1192109880 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $176,772.50 | 01/14/2025 | Non-covered Recipient Entity GI Reviewers | Phase 1b/3 Global, Randomized, Controlled, Open-label Trial Comparing Treatment With RYZ101 to Standard of Care Therapy in Subjects With Inoperable, Advanced, SSTR+, Well-differentiated GEP-NETs That Have Progressed Following Prior 177Lu-SSA Therapy | No dispute reported | 06/30/2026 | 1235997097 |
| Principal investigator 1 | Boehringer Ingelheim Espana S.A. | $3,500.00 | 01/09/2025 | Non-covered Recipient Entity GI Reviewers, LLC | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220577678 |